ArticleMolecular & cellular oncology2016
More challenges ahead-metabolic heterogeneity of pancreatic cancer stem cells.
Article in Molecular & cellular oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- Recent Updates on the Efficacy of Mitocans in Photo/Radio-therapy for Targeting Metabolism in Chemo/Radio-resistant Cancers: Nanotherapeutics.Current medicinal chemistry · 2025Review
- A protracted war against cancer drug resistance.Cancer cell international · 2024Review
- Cancer metabolism and carcinogenesis.Experimental hematology & oncology · 2024Review
- Integrated lipidomics and proteomics reveal cardiolipin alterations, upregulation of HADHA and long chain fatty acids in pancreatic cancer stem cells.Scientific reports · 2021Article
- Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy.Scientific reports · 2021Article
- Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Mitochondrial determinants of chemoresistance.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Review
- Rapid induction of pancreatic cancer cells to cancer stem cells via heterochromatin modulation.Cell cycle (Georgetown, Tex.) · 2018Article
- Isolation and identification of cancer stem cells from PC3 human prostate carcinoma cell line.International journal of clinical and experimental pathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer stem cells (CSCs) display a distinct metabolic phenotype based on their strong dependence on mitochondrial oxidative phosphorylation (OXPHOS) and limited metabolic plasticity. While suppression of MYC upstream of PGC-1α was the key determinant of this phenotype, we also identified a subset of CSCs with reduced mitochondrial content that showed resistance to mitochondrial targeting, but could be sensitized by inhibition of MYC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.